CN102459603B - 岩藻糖基化缺陷型细胞 - Google Patents

岩藻糖基化缺陷型细胞 Download PDF

Info

Publication number
CN102459603B
CN102459603B CN2010800294912A CN201080029491A CN102459603B CN 102459603 B CN102459603 B CN 102459603B CN 2010800294912 A CN2010800294912 A CN 2010800294912A CN 201080029491 A CN201080029491 A CN 201080029491A CN 102459603 B CN102459603 B CN 102459603B
Authority
CN
China
Prior art keywords
cells
cell
fucosylation
fucose
glycoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2010800294912A
Other languages
English (en)
Chinese (zh)
Other versions
CN102459603A (zh
Inventor
陈刚
D·布拉科夫
J·P·凡德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN102459603A publication Critical patent/CN102459603A/zh
Application granted granted Critical
Publication of CN102459603B publication Critical patent/CN102459603B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2010800294912A 2009-06-02 2010-06-01 岩藻糖基化缺陷型细胞 Expired - Fee Related CN102459603B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18340009P 2009-06-02 2009-06-02
US61/183,400 2009-06-02
US34885810P 2010-05-27 2010-05-27
US61/348,858 2010-05-27
PCT/US2010/036914 WO2010141478A1 (en) 2009-06-02 2010-06-01 Fucosylation-deficient cells

Publications (2)

Publication Number Publication Date
CN102459603A CN102459603A (zh) 2012-05-16
CN102459603B true CN102459603B (zh) 2013-11-06

Family

ID=42338231

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800294912A Expired - Fee Related CN102459603B (zh) 2009-06-02 2010-06-01 岩藻糖基化缺陷型细胞

Country Status (16)

Country Link
US (8) US8409838B2 (enExample)
EP (3) EP2438171B1 (enExample)
JP (4) JP5744856B2 (enExample)
KR (2) KR101441437B1 (enExample)
CN (1) CN102459603B (enExample)
AU (1) AU2010256753B2 (enExample)
BR (1) BRPI1010035A2 (enExample)
CA (1) CA2764370C (enExample)
DK (3) DK3279326T3 (enExample)
ES (2) ES2527173T3 (enExample)
HU (1) HUE038596T2 (enExample)
IL (1) IL216624A (enExample)
PL (3) PL2438171T3 (enExample)
SG (1) SG176251A1 (enExample)
TW (1) TWI513818B (enExample)
WO (1) WO2010141478A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140161782A1 (en) 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
BRPI1010035A2 (pt) 2009-06-02 2015-08-25 Regeneron Pharma Células deficientes em fucosilação
WO2012120500A2 (en) 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
EP2722673B1 (en) 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
WO2015057393A1 (en) * 2013-10-01 2015-04-23 University Of Wyoming Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production recombinant glycoproteins
RS59077B1 (sr) 2014-03-11 2019-09-30 Regeneron Pharma Anti-egfrviii antitela i njihova primena
EP3149034B1 (en) * 2014-05-30 2022-07-13 New England Biolabs, Inc. Deglycosylation reagents and methods
CN106687581A (zh) * 2014-07-07 2017-05-17 塔尔加泽梅股份有限公司 用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥
CN105671109B (zh) * 2014-11-20 2019-08-23 中国人民解放军军事医学科学院生物工程研究所 用糖基工程酵母制备具有动物细胞糖基化修饰流感血凝素糖蛋白的方法
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TWI899515B (zh) 2015-08-04 2025-10-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CN108431026B (zh) * 2015-11-02 2023-02-17 豪夫迈·罗氏有限公司 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法
EP3400241B1 (en) 2016-01-06 2020-07-22 Outlook Therapeutics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
SG11201807881VA (en) 2016-04-20 2018-10-30 Regeneron Pharma Compositions and methods for making antibodies based on use of an expression-enhancing locus
KR102906454B1 (ko) * 2016-04-20 2026-01-02 리제너론 파마슈티칼스 인코포레이티드 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
EP3339444A1 (en) * 2016-12-20 2018-06-27 Mabxience Research, S.L. Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans
KR20200135781A (ko) 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
KR102596303B1 (ko) * 2018-08-29 2023-10-30 유나이티드 바이오파마, 인크. 비푸코실화된 항체 및 그의 제조법
CA3118073A1 (en) 2018-10-29 2020-05-07 Immuno-Biological Laboratories Co., Ltd. Anti-hiv antibody and method for producing same
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
WO2021242815A1 (en) 2020-05-26 2021-12-02 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
JP2023528441A (ja) 2020-06-03 2023-07-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ＳＡＲＳ－ＣｏＶ－２スパイク糖タンパク質抗体を用いてＳＡＲＳ－ＣｏＶ－２感染及びＣＯＶＩＤ－１９を治療又は予防するための方法
CN112843234B (zh) * 2021-01-20 2022-09-06 四川大学华西第二医院 一种调控生物机体内gdp-甘露糖的浓度的装置
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CA3212850A1 (en) 2021-06-22 2022-12-29 Frank DELFINO Anti-egfrviii antibody drug conjugates and uses thereof
CA3225575A1 (en) 2021-07-14 2023-01-19 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023081434A2 (en) 2021-11-07 2023-05-11 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
AU2023228815A1 (en) 2022-03-02 2024-09-12 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1331266A1 (en) * 2000-10-06 2003-07-30 Kyowa Hakko Kogyo Co., Ltd Cells producing antibody compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1006070A (en) 1909-05-11 1911-10-17 George Walter Durbrow Method of and means for extracting micro-organisms and solids from water.
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP2001145488A (ja) 1999-11-19 2001-05-29 Natl Inst Of Advanced Industrial Science & Technology Meti シロイヌナズナ由来のｇｄｐ−４−ケト−６−デオキシ−ｄ−マンノース−３，５−エピメラーゼ−４−レダクターゼ遺伝子
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020150968A1 (en) 2001-01-10 2002-10-17 Wang Peng G. Glycoconjugate and sugar nucleotide synthesis using solid supports
WO2002057423A2 (en) 2001-01-16 2002-07-25 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
KR100585140B1 (ko) 2004-04-26 2006-05-30 삼성전자주식회사 와이어 본딩 장치 및 이를 이용한 반도체 패키지의 와이어본딩 방법
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
EP1888638A2 (en) 2005-06-03 2008-02-20 Genentech, Inc. Method of producing antibodies with modified fucosylation level
JP5825756B2 (ja) 2006-08-14 2015-12-02 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ１９を標的とする最適化抗体
RU2479629C2 (ru) 2007-03-07 2013-04-20 Гликофи, Инк. Продукция гликопротеинов с модифицированным фукозилированием
ES2522615T3 (es) 2007-06-04 2014-11-17 Regeneron Pharmaceuticals, Inc. Regiones de expresión y estabilidad potenciadas
EP2311864A4 (en) 2008-08-13 2013-07-31 Kyowa Hakko Kirin Co Ltd RECOMBINANT PROTEIN-S COMPOSITION
BRPI1010035A2 (pt) 2009-06-02 2015-08-25 Regeneron Pharma Células deficientes em fucosilação
WO2012120500A2 (en) 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1331266A1 (en) * 2000-10-06 2003-07-30 Kyowa Hakko Kogyo Co., Ltd Cells producing antibody compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Double knockdown of α1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC;Harue Imai-Nishiya et al.;《BMC Biotechnology》;20071130;第7卷;84 *
岩藻糖糖链与肝癌细胞的迁移作用;吴兴中等;《生物化学与生物物理进展》;20021231;第29卷(第6期);932-937 *
肝癌转移相关的核心岩藻糖基化蛋白质表达谱的研究;代智等;《生物化学与生物物理进展》;20051231;第32卷(第5期);442-448 *

Also Published As

Publication number Publication date
EP3279326B1 (en) 2020-10-14
EP2808393B1 (en) 2018-01-10
ES2661074T3 (es) 2018-03-27
DK3279326T3 (da) 2020-12-21
TWI513818B (zh) 2015-12-21
US20210254022A1 (en) 2021-08-19
KR20120029443A (ko) 2012-03-26
PL2808393T3 (pl) 2018-04-30
WO2010141478A1 (en) 2010-12-09
EP2438171A1 (en) 2012-04-11
KR20140039340A (ko) 2014-04-01
AU2010256753B2 (en) 2013-11-28
US20170211115A1 (en) 2017-07-27
JP2016104045A (ja) 2016-06-09
TW201107469A (en) 2011-03-01
HUE038596T2 (hu) 2018-10-29
US9206455B2 (en) 2015-12-08
PL3279326T3 (pl) 2021-03-08
SG176251A1 (en) 2011-12-29
ES2527173T3 (es) 2015-01-21
US20200080124A1 (en) 2020-03-12
JP2015051021A (ja) 2015-03-19
DK2808393T3 (en) 2018-03-12
US8409838B2 (en) 2013-04-02
BRPI1010035A2 (pt) 2015-08-25
US20230295583A1 (en) 2023-09-21
EP2438171B1 (en) 2014-12-17
JP5744856B2 (ja) 2015-07-08
EP2808393A2 (en) 2014-12-03
US12054751B2 (en) 2024-08-06
EP2808393A3 (en) 2015-03-11
KR101641526B1 (ko) 2016-07-21
HK1163745A1 (en) 2012-09-14
JP2017006147A (ja) 2017-01-12
CA2764370C (en) 2018-08-21
HK1198180A1 (en) 2015-03-13
CA2764370A1 (en) 2010-12-09
US9550823B2 (en) 2017-01-24
US20100304436A1 (en) 2010-12-02
AU2010256753A1 (en) 2012-01-12
JP6211642B2 (ja) 2017-10-11
IL216624A (en) 2015-02-26
HK1249547A1 (en) 2018-11-02
US20130164786A1 (en) 2013-06-27
US10006070B2 (en) 2018-06-26
DK2438171T3 (en) 2015-01-26
JP2012528594A (ja) 2012-11-15
KR101441437B1 (ko) 2014-09-25
US20190024129A1 (en) 2019-01-24
US11560550B2 (en) 2023-01-24
PL2438171T3 (pl) 2015-04-30
IL216624A0 (en) 2012-02-29
US20160090410A1 (en) 2016-03-31
CN102459603A (zh) 2012-05-16
EP3279326A1 (en) 2018-02-07

Similar Documents

Publication Publication Date Title
US12054751B2 (en) Fucosylation-deficient cells
AU2015282354B2 (en) Fucosylation-deficient cells
AU2012100020A6 (en) Fucosylation-deficient cells
HK1249547B (en) Fucosylation-deficient cells
HK1198180B (en) Fucosylation-deficient cells
HK1163745B (en) Fucosylation-deficient cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131106